Matches in SemOpenAlex for { <https://semopenalex.org/work/W4220794879> ?p ?o ?g. }
Showing items 1 to 86 of
86
with 100 items per page.
- W4220794879 endingPage "7051" @default.
- W4220794879 startingPage "7047" @default.
- W4220794879 abstract "Antiresorptive drugs (bisphosphonates and denosumab) have become the cornerstone of medical supportive treatment of bone metastases in solid cancer patients. In the beginning, the choice of available antiresorptive agents was limited to bisphosphonates and the treatment options restricted principally to monthly pamidronate and monthly zoledronic acid. Introduction of new antiresorptive therapies (monthly denosumab) and schedules (zoledronic acid every 3 months, upfront or after initial period of monthly infusion) in the last decade increased the range of available options, thus challenging treatment decision making. Direct and indirect costs of very different treatment options are difficult to interpret in a global cost-benefit analysis. In addition, awareness of the increased risk of medication-related osteonecrosis of the jaw (MRONJ) in bone metastatic cancer patients receiving long-term antiresorptive medications is likely to influence therapy choice in the real-life scenario. We discuss the possible threat of MRONJ risk underestimation and the need for long-term risk stratification of patients based on actuarial data, the role of bisphosphonates and denosumab in that scenario, and the emerging role of surgical therapy to successfully cure MRONJ, in the light of the improved quality of life and survival of patients with bone metastases from solid cancers." @default.
- W4220794879 created "2022-04-03" @default.
- W4220794879 creator A5025486771 @default.
- W4220794879 creator A5062414404 @default.
- W4220794879 creator A5067216676 @default.
- W4220794879 date "2022-03-21" @default.
- W4220794879 modified "2023-10-16" @default.
- W4220794879 title "One changing and challenging scenario: the treatment of cancer patients with bone metastases by bisphosphonates and denosumab, the cost–benefit evaluation of different options, and the risk of medication-related osteonecrosis of the jaw (MRONJ)" @default.
- W4220794879 cites W2734610622 @default.
- W4220794879 cites W2758430172 @default.
- W4220794879 cites W2765774285 @default.
- W4220794879 cites W2886370075 @default.
- W4220794879 cites W2886896376 @default.
- W4220794879 cites W2943344648 @default.
- W4220794879 cites W2963368473 @default.
- W4220794879 cites W2964009193 @default.
- W4220794879 cites W3001426185 @default.
- W4220794879 cites W3003573098 @default.
- W4220794879 cites W3048934302 @default.
- W4220794879 cites W3096118624 @default.
- W4220794879 cites W3100646092 @default.
- W4220794879 cites W3120383256 @default.
- W4220794879 cites W3129184317 @default.
- W4220794879 cites W3132396655 @default.
- W4220794879 cites W3146116948 @default.
- W4220794879 cites W3155285642 @default.
- W4220794879 cites W3170685084 @default.
- W4220794879 cites W3176832766 @default.
- W4220794879 cites W3210939773 @default.
- W4220794879 doi "https://doi.org/10.1007/s00520-022-06982-y" @default.
- W4220794879 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35312858" @default.
- W4220794879 hasPublicationYear "2022" @default.
- W4220794879 type Work @default.
- W4220794879 citedByCount "9" @default.
- W4220794879 countsByYear W42207948792022 @default.
- W4220794879 countsByYear W42207948792023 @default.
- W4220794879 crossrefType "journal-article" @default.
- W4220794879 hasAuthorship W4220794879A5025486771 @default.
- W4220794879 hasAuthorship W4220794879A5062414404 @default.
- W4220794879 hasAuthorship W4220794879A5067216676 @default.
- W4220794879 hasBestOaLocation W42207948791 @default.
- W4220794879 hasConcept C126322002 @default.
- W4220794879 hasConcept C143998085 @default.
- W4220794879 hasConcept C159110408 @default.
- W4220794879 hasConcept C177713679 @default.
- W4220794879 hasConcept C2776286101 @default.
- W4220794879 hasConcept C2776326535 @default.
- W4220794879 hasConcept C2776541429 @default.
- W4220794879 hasConcept C2777251235 @default.
- W4220794879 hasConcept C2777556957 @default.
- W4220794879 hasConcept C2779951463 @default.
- W4220794879 hasConcept C71924100 @default.
- W4220794879 hasConceptScore W4220794879C126322002 @default.
- W4220794879 hasConceptScore W4220794879C143998085 @default.
- W4220794879 hasConceptScore W4220794879C159110408 @default.
- W4220794879 hasConceptScore W4220794879C177713679 @default.
- W4220794879 hasConceptScore W4220794879C2776286101 @default.
- W4220794879 hasConceptScore W4220794879C2776326535 @default.
- W4220794879 hasConceptScore W4220794879C2776541429 @default.
- W4220794879 hasConceptScore W4220794879C2777251235 @default.
- W4220794879 hasConceptScore W4220794879C2777556957 @default.
- W4220794879 hasConceptScore W4220794879C2779951463 @default.
- W4220794879 hasConceptScore W4220794879C71924100 @default.
- W4220794879 hasIssue "9" @default.
- W4220794879 hasLocation W42207948791 @default.
- W4220794879 hasLocation W42207948792 @default.
- W4220794879 hasLocation W42207948793 @default.
- W4220794879 hasLocation W42207948794 @default.
- W4220794879 hasOpenAccess W4220794879 @default.
- W4220794879 hasPrimaryLocation W42207948791 @default.
- W4220794879 hasRelatedWork W2015998783 @default.
- W4220794879 hasRelatedWork W2031209970 @default.
- W4220794879 hasRelatedWork W2274443098 @default.
- W4220794879 hasRelatedWork W2493633823 @default.
- W4220794879 hasRelatedWork W2511450667 @default.
- W4220794879 hasRelatedWork W2790124499 @default.
- W4220794879 hasRelatedWork W3129184317 @default.
- W4220794879 hasRelatedWork W3138278265 @default.
- W4220794879 hasRelatedWork W4226070154 @default.
- W4220794879 hasRelatedWork W4379162874 @default.
- W4220794879 hasVolume "30" @default.
- W4220794879 isParatext "false" @default.
- W4220794879 isRetracted "false" @default.
- W4220794879 workType "article" @default.